Merck KGaA: Raising Guidance and Pivoting to Life Science
A robust Q2 with accelerated growth, a raised full-year outlook, and the Bio-Techne acquisition reshaping the portfolio.
MRK.DE · Earnings Call · 2026-08-06
A Solid Quarter, A Raised Bar
Merck KGaA delivered a robust Q2 2026, accelerating organic sales growth to 4.1% and expanding EBITDA pre margin by 1.6 points to 29.4%. The company raised full-year guidance, now expecting organic group sales growth of 1% to 3% (from 0% to 3%) and EBITDA pre of EUR 5.9–6.3 billion. As “we now expect organic growth in group net sales of 1% to 3% compared with 0% to 3% previously” — Kai Beckmann, Group CEO · 2026-08-06 – a clear signal that momentum is building. The bright spot is Process Solutions, which grew 15% organically in the quarter, but management is careful to distinguish underlying strength from temporary tailwinds. The order book is healthy, but “we do not anticipate any destocking effect in 2026. But you should assume in your model that if we have some inventory destocking effect, it may take place in 2027” — Jean Wirth, Executive in Process Solutions or Life Science · 2026-08-06 – a caveat that investors will need to weigh.The Bio-Techne Pivot
The most significant strategic move is the planned acquisition of Bio-Techne, signed in June. The deal is expected to be immediately accretive to sales growth and margins. Kai Beckmann noted, “Bio-Techne's complementary portfolio of high-quality reagents, analytical instruments and diagnostic systems for precision medicine is expected to be immediately accretive to sales growth and margins” — Kai Beckmann, Group CEO · 2026-08-06 – though the transaction still requires regulatory approval and closing is targeted for year-end or early 2027. Management's commitment to Life Science is reinforced by the new Bio Techne integration plans. Jean-Charles Wirth, CEO of Life Science, is already optimistic about the combined offering, but the near-term focus remains on executing the integration and delivering the EUR 140 million run-rate synergies by year 3.Electronics and Semi Solutions: Riding the AI Wave
Electronics delivered a standout quarter, with organic growth accelerating to 12%, driven by Semi Solutions (+17%). The company is benefiting from continued AI-related demand for advanced semiconductor materials. “By and large, especially the leading-edge customers that contribute to the AI-driven growth remain capacity constrained, both this year into the second half as well as well into 2027” — Danny Bar-Zohar, Executive in Healthcare or Pharmaceuticals · 2026-08-06 – a strong signal that the semi cycle has legs. This is in line with the global trajectory of Semi Solutions being a key growth driver. The raised Electronics guidance to 6%–9% organic sales growth reflects confidence in this momentum.Healthcare: Managing the Transition
Healthcare remains the weak link, with organic sales declining 3.4% due to MAVENCLAD's loss of exclusivity in the U.S. and competition for BAVENCIO. However, the rare disease portfolio is a bright spot, with OGSIVEO and GOMEKLI combining for EUR 207 million in H1. The pipeline is advancing, including the Phase III start for colorectal cancer asset Precem-TcT, and the FDA granted breakthrough therapy designation to enpatoran. There is also significant uncertainty over the potential U.S. approval of Pergoveris. In the Q&A, Danny Bar-Zohar described the situation: “there is considerable uncertainty ... about whether the package now is sufficient for the FDA to approve” — Danny Bar-Zohar, Executive in Healthcare or Pharmaceuticals · 2026-08-06. That said, management remains disciplined, maintaining healthcare EBITDA pre margins above 30% while investing in launches and pipeline.2027 Visibility
When pressed on 2027, Kai Beckmann pointed to the CMD commitments:. This is a clear signal that the company views the current momentum as durable, even as it cycles tough comparables. Prior calls had flagged similar risks. In May, Jean-Charles Wirth explained that Q1 Process Solutions had “three effects: operational efficiency gains, new customer projects, and stronger buying patterns from APAC customers.” — Jean-Charles Wirth, Executive · 2026-05-13 And on Pergoveris, Danny Bar-Zohar had previously noted the constructive exchange with the FDA, but the uncertainty remains (component 2970569128970316329).2027 should be well in line with our projections from last year's CMD ... Bio-Techne would add close to 5% to group sales growth and about 10% to Life Science alone